PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) is a therapeutic target to which HER2/HER3 activation may contribute resistance. This Phase I/II study examined the toxicity and efficacy of high-dose pulsed AZD8931, an EGFR/HER2/HER3 inhibitor, combined with chemotherapy, in metastatic colorectal...

Descripción completa

Detalles Bibliográficos
Autores principales: Propper, David J., Gao, Fangfei, Saunders, Mark P., Sarker, Debashis, Hartley, John A., Spanswick, Victoria J., Lowe, Helen L., Hackett, Louise D., Ng, Tony T., Barber, Paul R., Weitsman, Gregory E., Pearce, Sarah, White, Laura, Lopes, Andre, Forsyth, Sharon, Hochhauser, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902557/
https://www.ncbi.nlm.nih.gov/pubmed/36352028
http://dx.doi.org/10.1038/s41416-022-02015-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902557/
https://www.ncbi.nlm.nih.gov/pubmed/36352028
http://dx.doi.org/10.1038/s41416-022-02015-x

Ejemplares similares